PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20067122-0	2009	[Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].	Ceftriaxone	86-97	beta-lactamase	Escherichia coli	112-126	
20067122-1	2009	OBJECTIVE: To study post antibiotic effect (PAE), post beta-lactamase inhibitor effect (PLIE) and post antibiotic sub-MIC effect (PASME) of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro.	Ceftriaxone	140-151	beta-lactamase	Escherichia coli	166-180	
20067122-2	2009	METHODS: The minimal inhibitory concentration (MIC) of ceftriaxone/tazobactam against 4 types of beta-lactamase producing E. coli strains, was measured by two-fold agar dilution method.	Ceftriaxone	55-66	beta-lactamase	Escherichia coli	97-111	
30068589-4	2018	E. coli cells carrying the beta-lactamase triple mutant G238S:E240:R241G show increased resistance to cefotaxime and ceftriaxone, two cephalosporins, compared with wild-type cells.	Ceftriaxone	117-128	beta-lactamase	Escherichia coli	27-41	
10103209-1	1999	DNA sequencing data showed that five clinical isolates of Escherichia coli with reduced susceptibility to ceftazidime, ceftriaxone, and cefotaxime contain an ampC gene that is preceded by a strong promoter.	Ceftriaxone	119-130	beta-lactamase	Escherichia coli	158-162